Page last updated: 2024-10-31

metyrapone and Migraine Disorders

metyrapone has been researched along with Migraine Disorders in 1 studies

Metyrapone: An inhibitor of the enzyme STEROID 11-BETA-MONOOXYGENASE. It is used as a test of the feedback hypothalamic-pituitary mechanism in the diagnosis of CUSHING SYNDROME.
metyrapone : An aromatic ketone that is 3,3-dimethylbutan-2-one in which the methyl groups at positions 1 and 4 are replaced by pyridin-3-yl groups. A steroid 11beta-monooxygenase (EC 1.14.15.4) inhibitor, it is used in the diagnosis of adrenal insufficiency.

Migraine Disorders: A class of disabling primary headache disorders, characterized by recurrent unilateral pulsatile headaches. The two major subtypes are common migraine (without aura) and classic migraine (with aura or neurological symptoms). (International Classification of Headache Disorders, 2nd ed. Cephalalgia 2004: suppl 1)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19901 (100.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Rao, NS1
Pearce, J1

Trials

1 trial available for metyrapone and Migraine Disorders

ArticleYear
Hypothalamic-pituitary-adrenal axis studies in migraine with special reference to insulin sensitivity.
    Brain : a journal of neurology, 1971, Volume: 94, Issue:2

    Topics: Adult; Blood Glucose; Clinical Trials as Topic; Female; Humans; Hydrocortisone; Hypoglycemia; Hypoth

1971